Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

gnosed autoimmune type 1 diabetes," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx.

For additional information about DEFEND, please visit http://www.DefendAgainstDiabetes.com.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. There are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder of the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. The decrease in endogenous (natural) insulin production means that patients must monitor their glucose levels frequently and take insulin regularly to control their blood glucose levels.

About Otelixizumab

Otelixizumab is a monoclonal antibody that binds to CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab is thought to work by blocking the function of effector T cells that attack the body's tissues and cause autoimmune disease while inducing a subset of T cells known as regulatory T cells. It is thought that the regulatory T cells may protect against effector T cell damage well after the antibody has been eliminated from the body. In addition to DEFEND, Tolerx is also continuing to evaluate otelixizumab in subjects with type 1 diabetes in its ongoing Phase 2 study, TTEDD (TRX4 Therapeutic Evaluation of Different Dosing Regimens). A principal purpose of TTEDD is to evaluate different dosing regimens in an effort to reduce side effects and to acquire additional information about otelixizumab's clinical activity. Tolerx has conducted dose optimization studies in type 1 diabetes and has identified a dosing regimen that thus far has significantly reduced side effects while maintaining im
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... MOUNTAIN VIEW, Calif. , Oct. 22, ... 11:00 a.m. EDTLOCATION: Online, complimentary registration available ... Group Team Leader Archana Vidyasekar and Visionary ... VargheseBrain-controlled computers, WiFi-like wireless electricity, self-assembling materials, ... top ten technologies which will transform our ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
(Date:10/22/2014)... CAMBRIDGE, Mass. and SHANGHAI ... Inc. (NASDAQ: FMI ) and WuXi ... announced a collaboration to offer Foundation Medicine,s comprehensive genomic ... China . Under the ... enable WuXi to perform the laboratory component of Foundation ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... Inc. (Inspiration) announced today that the European Commission has ... of hemophilia.  Expected to enter pivotal clinical trials before ... treat individuals with hemophilia who have developed inhibitors against ... trigger a 10-year market exclusivity for OBI-1 in the ...
... DIEGO, Oct. 19 Aethlon Medical, Inc. (OTC Bulletin ... therapeutic filtration devices to address infectious disease and cancer, ... the Aethlon Medical board of directors. ... ) Mr. Kenley has 33 years of ...
Cached Medicine Technology:Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe 2Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe 3Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 2Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 3Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 4Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors 5
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... ... Announced That It Has Been Selected As A 2010 Emerging Technology Vendor By CRN Magazine. ... Philadelphia, PA (PRWEB) July ... announced that it has been selected as a 2010 Emerging Technology Vendor by CRN Magazine. ...
... , ... Association HealthCare Professionals (IAHCP) welcomes esteemed psychiatrist Dr. Lyubov Gorelik into the pages thier ... representing New York State as a leader in psychiatry, and will be featured alongside ... ...
... ... Oxford House , ... 3, 2010 -- “Oxford House is a true blessing for those who really want recovery.” This ... Today, author Joe Chavez shares their stories in I Second The Motion: Learning to Live Sober, ...
... Featuring over 200 ... need of a mobility solution for their home. Customers will benefit from exclusive catalog pricing ... ... retailer of more than 10,000 medical and mobility products, announced the publication of its 2010 ...
... Anthony Booth, a ... the aisle thanks to Leeds Teaching Hospitals Trust and Leeds based prosthetics specialists RSLSteeper. A ... new limbs. , ... 6, 2010 -- Leeds Teaching Hospitals Trust and RSLSteeper team up to help Paralympian walk ...
... (WASHINGTON, July 1, 2010) Older patients with Hodgkin ... high risk of hospitalization for cardiac complications after completing treatment, ... the journal of the American Society of Hematology. HL is ... and approximately 8,500 people were diagnosed with the disease in ...
Cached Medicine News:Health News:Neuxpower Selected as 2010 Emerging Technology Vendor by CRN Magazine 2Health News:Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World 2Health News:Oxford House: Where Stories of Recovery Are Born 2Health News:US Medical Supplies Publishes 2010 Catalog 2Health News:Leeds Teaching Hospitals Trust and RSLSteeper Team Up to Help Paralympian Walk His Sister Down the Aisle 2Health News:Leeds Teaching Hospitals Trust and RSLSteeper Team Up to Help Paralympian Walk His Sister Down the Aisle 3Health News:Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization 2
... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Weck-Cel Triangle shaped spearhead, set on a malleable, polypropylene handle, is designed for use in delicate, surgical areas. Maintains rigidity during wicking process. Single use, packaged sterile....
Medicine Products: